Kinase inhibitors in rheumatoid arthritis: where have they been and where are they going?

01 Jul 2015 by Gunilla Sturrock

Topics: Clinical Trial Optimization |

Provided by Trialtrove: gold standard clinical trials intelligence |

This important white paper provides an analysis of kinase inhibitor trials for the management of rheumatoid arthritis, which have been discontinued and why, and which hold promise for easing the symptoms of this chronically progressive disease.

Highlights in this white paper include:

Phase II to III kinase inhibitor trials in RA initiated since mid-2010
Kinase inhibitors in active late stage development for RA
Kinase inhibitors discontinued for RA, and why
Trial sponsors who are having the greatest success and more

July-2015_Kinese-Inhibitors-in-RA_Gunilla-Sturrock

Download white paper

Next steps

Request a Demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 212-600-3520
UK & Europe : +44 (20) 805 20700
Australia : +61 2 8705 6907

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Kinase inhibitors in rheumatoid arthritis: where have they been and where are they going?

Highlights in this white paper include:

Next steps

This is Contactus Section

Request a Demo

How can we help you?

Pharma Report Store

Datamonitor Healthcare: data analysis and insight

Citeline

Pharmaprojects: track pharma R&D

Kinase inhibitors in rheumatoid arthritis: where have they been and where are they going?

Highlights in this white paper include:

Next steps

This is Contactus Section

Request a Demo

How can we help you?

Pharma Report Store

Related Products

Datamonitor Healthcare: data analysis and insight

Citeline

Pharmaprojects: track pharma R&D